Nasdaq
$28.79▼ 1.57%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.40BShares out 48.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 4d agoAfter-hours26.10.21 05:156-KKey event#●●●
Nanobiotix S.A.
Nanobiotix S.A. has disclosed its total number of outstanding shares and voting rights as of September 30, 2026, in accordance with French Commercial Code and AMF regulations. As of that date, the company had 50,967,610 shares outstanding with 54,707,425 exercisable voting rights.…more
$28.79-1.57%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 05:306-KKey event
Nanobiotix S.A.
Nanobiotix announced the appointment of Arnd Christ as Chief Financial Officer and member of the executive board, effective October 1, 2026. He succeeds Bart Van Rhijn, who is stepping down after five years of service to the company.…more
$28.79-1.57%vs prev closeView filingShare - 9.24After-hours26.09.25 05:176-KKey event
Nanobiotix S.A.
Nanobiotix S.A. has released its financial results for the first half of 2026. During this period, the company reported a net loss driven by ongoing research, development, and operational expenses, while disclosing the status of its major liabilities and financing activities.…more
$28.79-1.57%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 23h agoClosed26.10.24 20:00#●●●#●●●
Nanobiotix Reports Final Phase 1 Data for JNJ-1900 in Melanoma
Nanobiotix announced positive early efficacy and safety signals from its Phase 1 study of JNJ-1900 in patients with anti-PD-1-resistant melanoma. These preliminary results from a single-arm study warrant further evaluation in larger randomized clinical trials.…more
$28.79-1.57%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoAfter-hours26.10.21 05:15
●●●●●●●● ●●●●● ●●●●●●
Nanobiotix has released its total number of outstanding shares and voting rights as of September 30, 2026, in compliance with French regulatory requirements. This is a routine corporate disclosure and does not have a direct impact on the stock price.…more
$28.79-1.57%vs prev close - 10.1After-hours26.10.02 05:15
●●●●●●●● ●●●●● ●●●●●●
Nanobiotix has appointed Arnd Christ, a veteran with over 25 years of financial leadership experience in the biotech industry, as its new Chief Financial Officer. This leadership change is intended to strengthen the company's financial foundation as it enters its next phase of growth.…more
$28.79-1.57%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report